Avidity Biosciences recently joined PPMD for a community webinar to share topline data from their EXPLORE44® clinical trial, which is assessing the safety and efficacy of the investigational therapy delpacibart zotadirsen (formerly AOC 1044, abbreviated as del-zota) in people living with Duchenne mutations amenable to exon 44 skipping. The Avidity team shared background information about del-zota and the EXPLORE44 study, provided an overview of results, and answered questions from the community.
- Catégories
- Webinar
Ajouter un commentaire
Up Next
Autoplay
-
1:23:31
PATS Webinar - Clinical Genetics
-
1:01:56
86th SPSR Webinar on Decentralized Clinical Trials and Beyond: Transforming Clinical Research
-
30:39
Implementing the new UK Clinical Trials Regulations Webinar
-
48:55
Ahmed ClearPath® Clinical Data and Techniques - ClearPath Conversations Webinar Series, Episode 1
-
57:33
Live Webinar : Mastering Clinical Data Management: Trends, Tools & Career Pathways
-
1:30:45
ML ACADÉMIE FORMATION E-COMMERCE EN LIGNE, ENTREPRENDRE, GESTION PAGE, FRELENCE & COACHING WEBINAIRE
-
01:06
DESACTIVER Facebook RENCONTRE, comment mettre en pause son profil ou un compte Facebook Dating
-
13:35
Tuto Complet #3 - Les Projections D'Hosoda (Avec Ichimoku)
-
18:53
Un Business Ultra Rentable à Lancer en Afrique : Gagne 1 750 000 FCFA Par Mois
-
04:35
Guadagna con l'affiliazione Agrieuro
Chargement...
Commentaires